Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.

@article{Lana2007ContinuousLO,
  title={Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.},
  author={Susan E Lana and Lance U'ren and Susan Plaza and Robyn Elmslie and Daniel J. Gustafson and P. D. Morley and Steven B. Dow},
  journal={Journal of veterinary internal medicine},
  year={2007},
  volume={21 4},
  pages={764-9}
}
BACKGROUND Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor in dogs. At present, conventional adjuvant chemotherapy provides only a modest survival benefit for treated dogs. Continuous oral administration of low-dose chemotherapy (LDC) has been suggested as an alternative to conventional chemotherapy protocols. Therefore, we evaluated the safety and effectiveness of LDC using a combination of cyclophosphamide, etoposide, and piroxicam as adjuvant therapy for dogs with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS